|
| 基于Meta分析的伊立替康联合铂类一线治疗广泛期小细胞肺癌临床评价研究 |
| Meta analysis of Irinotecan/platinum in the First line Therapy of Extensive stage Small Cell Lung Cancer |
| |
| DOI： |
| 中文关键词: 小细胞肺癌 伊立替康 依托泊苷 Meta分析 |
| 英文关键词:Small cell lung cancer Irinotecan Etoposide Meta analysis |
| 基金项目:湖北省自然科学基金项目（编号：2016CFB137） |
|
| 摘要点击次数: 936 |
| 全文下载次数: 947 |
| 中文摘要: |
| 摘 要 目的：采用Meta分析方法评价伊立替康联合铂类一线治疗广泛期小细胞肺癌的临床疗效和安全性。方法：计算机检索中国期刊全文数据库（CNKI）、万方数据库、中国生物医学文献数据库（SinoMed）、PubMed、the Cochrane Library和Embase中有关伊立替康联合铂类对比依托泊苷联合铂类治疗广泛期小细胞肺癌的RCTs，对纳入文献进行质量评价，提取资料并通过RevMan 5.3软件进行数据分析。结果：共纳入7篇文献，累计1 881例受试者。Meta分析显示：伊立替康联合铂类一线治疗广泛期小细胞肺癌的疗效要优于依托泊苷联合铂类，可提高患者的2年总生存率（RR=1.19，95%CI：1.06~1.34, P=0.003），但是伊立替康联合铂类会增加化疗所致3~4度腹泻不良反应的发生率（RR=8.03，95%CI：3.18~20.27，P<0.000 01）。结论：伊立替康联合铂类一线治疗广泛期小细胞肺癌具有良好的疗效，但仍需警惕其不良反应。 |
| 英文摘要: |
| ABSTRACT Objective:To systematically assess the clinical effectiveness and safety of irinotecan/platinum in patients of extensive stage small cell lung cancer (ES-SCLC). Methods:A thorough and systematic review of randomized controlled trials (RCT) regarding irinotecan/platinum in the treatment of ES-SCLC were searched in CNKI, Wanfang, SinoMed, the Cochrane Library and Embase. The quality of included RCTs was evaluated, and then the data were extracted and Meta analysed by RevMan 5.3 software. Results:A total of 7 RCTs with 1 881 patients with previously untreated ES-SCLC were analyzed. Irinotecan/platinum(IP) could achieve a better effect than etoposide/platinum (EP) in the aspect of 2 years overall survival (RR=1.19, 95%CI: 1.06-1.34, P=0.003). But IP could add the risk of 3-4 degree diarrhea related to chemotherapy (RR=8.03, 95%CI: 5.39 14.08. P<0.000 01). Conclusion:The IP regimens could achieve a better clinical effectiveness in the first line treatment of ES-SCLC, but the adverse reactions should be alerted. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
